Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 610 across all filing types
Latest filing 2024-06-14 Board/Management Inform…
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Alligator Bioscience Apppoints Johan Giléus as Chief Financial Officer
Board/Management Information Classification · 1% confidence The document is a press release dated June 14, 2024, announcing the appointment of Johan Giléus as the new Chief Financial Officer (CFO) of Alligator Bioscience, succeeding Marie Svensson. This content directly relates to changes in senior management personnel. Based on the provided definitions, this clearly falls under 'Board/Management Information' (Code: MANG). The document is not a full annual report (10-K), an earnings release (ER), or a transcript (CT).
2024-06-14 English
Alligator Bioscience utser Johan Giléus till Chief Financial Officer
Board/Management Information Classification · 1% confidence The document is a press release dated June 14, 2024, announcing the appointment of Johan Giléus as the new Chief Financial Officer (CFO) of Alligator Bioscience, effective August 12, 2024. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The document is a formal announcement, not a full financial report (like 10-K or IR) or a transcript. Therefore, the appropriate code is MANG.
2024-06-14 Swedish
Bulletin from the annual general meeting in Alligator Bioscience AB on 7 May 2024
AGM Information Classification · 1% confidence The document is explicitly titled "BULLETIN FROM THE ANNUAL GENERAL MEETING IN ALLIGATOR BIOSCIENCE AB ON 7 MAY 2024". It details the resolutions passed regarding the adoption of accounts, election of board members, remuneration, approval of remuneration reports, and authorizations for share issues/warrants, all typical items discussed and voted upon at an Annual General Meeting (AGM). Although it contains elements related to remuneration (DEF 14A) and share issues (SHA/POS), the overarching context and structure are that of a summary of the AGM proceedings. Therefore, the most appropriate classification is AGM Information (AGM-R).
2024-05-07 English
Kommuniké från årsstämma den 7 maj 2024 i Alligator Bioscience AB
AGM Information Classification · 1% confidence The document is explicitly titled "KOMMUNIKÉ FRÅN ÅRSSTÄMMA DEN 7 MAJ 2024 I ALLIGATOR BIOSCIENCE AB" (Communiqué from the Annual General Meeting on May 7, 2024, in Alligator Bioscience AB). It details the resolutions passed at the AGM, including financial approvals, board elections, remuneration decisions, and authorization for share issues/option programs. This content directly corresponds to the definition of AGM Information, which covers presentations and materials shared during the Annual General Meeting. The code for this is AGM-R.
2024-05-07 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for the period January–March 2024 for Alligator Bioscience AB. It contains comprehensive financial statements, key performance indicators (KPIs), management commentary (Vd-ord), and operational updates. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2024
2024-05-06 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim report January – March 2024' and contains comprehensive financial statements, including income statements, cash flow data, and balance sheet metrics for the specified period. It also includes management commentary, operational updates, and pipeline project details. As it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2024
2024-05-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.